摘要
前列腺特异性抗原 (PSA) 已被认为是区分前列腺癌的关键血清学标志物。 该调查显示了基于纳米材料的 PSA 电化学免疫传感器构建的最新进展。 本综述(2015 年至 2020 年)报告了基于使用不同类型纳米结构材料的 PSA 传感的最新进展。 最常用的纳米结构材料是金属、金属氧化物、碳基纳米材料,以及它们用于不同放大协议的混合结构。 在这篇综述中,用于前列腺特异性抗原传感的电化学免疫传感器分为三类,如夹心型@标记、无标记@非标记和基于适体的电化学免疫传感器。
关键词: 前列腺特异性抗原、癌症标志物、免疫传感器、免疫测定、纳米材料、纳米技术。
Current Medicinal Chemistry
Title:Electrochemical Immunosensors Based on Nanostructured Materials for Sensing of Prostate-Specific Antigen: A Review
Volume: 28 Issue: 20
关键词: 前列腺特异性抗原、癌症标志物、免疫传感器、免疫测定、纳米材料、纳米技术。
摘要: The prostate-specific antigen (PSA) has been considered a crucial serological marker for distinguishing prostate based cancer. This survey shows recent progress in the construction of nanomaterial-based electrochemical immunosensors for a PSA. This review (from 2015 to 2020) reports the latest progress in PSA sensing based on the employ of different types of nanostructured materials. The most popular used nanostructured materials are metal, metal oxide, carbon-based nanomaterials, and their hybrid architectures utilized for distinct amplification protocols. In this review, the electrochemical immunosensors for prostate-specific antigen sensing are classified into three categories such as sandwich type@labeled, label free@nonlabeled and aptamer-based electrochemical immunosensor.
Export Options
About this article
Cite this article as:
Electrochemical Immunosensors Based on Nanostructured Materials for Sensing of Prostate-Specific Antigen: A Review, Current Medicinal Chemistry 2021; 28 (20) . https://dx.doi.org/10.2174/0929867328666201124151821
DOI https://dx.doi.org/10.2174/0929867328666201124151821 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections
Inflammation & Allergy - Drug Targets (Discontinued) DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets The Tribbles-1 Protein in Humans: Roles and Functions in Health and Disease
Current Molecular Medicine [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
Current Stem Cell Research & Therapy Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Carcinogenesis and Therapeutic Strategies in Thyroid Cancer
Current Drug Targets NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Comprehensive Profiling of the Low Molecular Weight Proteins and Peptides in Weak Cation Exchange Beads Human Serum Retentate
Protein & Peptide Letters Antisense Technology: A Selective Tool for Gene Expression Regulation and Gene Targeting
Current Pharmaceutical Biotechnology The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
Current Pharmaceutical Design Synergism from Combination of Cisplatin and Multicentred Platinums Coded as DH6Cl and TH1 in the Human Ovarian Tumour Models
Medicinal Chemistry Advances in Exploring the Role of Micrornas in Inflammatory Bowel Disease
MicroRNA IDO+ DCs and Signalling Pathways
Current Cancer Drug Targets